FGFR2 and gastric adenocarcinoma: The SHINE study (NCT01457846), a comparative randomized, open-label, phase II study of the efficacy and safety of AZD4547 versus paclitaxel for advanced gastric adenocarcinoma with FGFR2 polysomy or gene amplification, showed no significant benefits in progression-free survival (PFS) for AZD4547 monotherapy.